The addition of topotecan to carboplatin and paclitaxel as first-line therapy for advanced ovarian cancer; is it possible only with peripheral blood stem cell support?

A phase I study was performed in order to evaluate the tolerability of the combination of fixed doses of carboplatin and paclitaxel and escalated doses of topotecan as first line chemotherapy for advanced epithelial ovarian cancer. Three stage III and one stage IV patients entered the study. The dose limiting toxicity (neutropenia and thrombocytopenia) was reached at the first dose level: paclitaxel 175 mg/m2 on day 1, carboplatin AUC 5 on day I and topotecan 0.5 mg/m2 daily from day 1 to day 3. We conclude that it is not possible to add topotecan to standard regimens of carboplatin and paclitaxel without bone marrow support.

Topotecan; Paclitaxel; Carboplatin; Polychemotherapy; Ovarian cancer

[1] ten Bokkel Huinink W. W. Gore M., Carmichael J. et al.: "Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer". J. Clin. Oneal., 1997, 15, 2183.

[2] Zamagni C., Martoni A., Cacciari N., Gentile A. and Pannuti F.: "The combination of paclitaxel and carboplatin as first line chemotherapy in patients with stage III and IV ovarian cancer: a phase I-II study". Am. J. Clin. Oneal., 1998, 21, 491.

[3] Armstrong D. K., O'Reilly S., Bookman M. et al.: "A phase I study of topotecan, cisplatin and paclitaxel in newly diagnosed epithelial ovarian cancer, a Gynecologic Oncology Group (GOG 9602) study". Proceedings of ASCO, 17 (abst. 1351) 1998.

[4] ten Bokkel Huinink W.W., Richel D. J., Herben V. M. M. et al.: "Feasibility study of the combination of cisplatin, paclitaxel and topotecan in ovarian cancer patients". Proceedings of ASCO 17 (abst. 1353) 1998.

[5] Schilder R. J., Gallo J.M., Johnson S. W. et al.: "Phase I study of multiple cycles of high dose topotecan, carboplatin and paclitaxel with peripheral blood stem cell support". Proceedings of ASCO 17 (abst. 290) 1998.